Survival analyses from the ZEBRA study
- 1 August 2003
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (12), 1711-1717
- https://doi.org/10.1016/s0959-8049(03)00392-7
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5Journal of Clinical Oncology, 2002
- Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association StudyJournal of Clinical Oncology, 2002
- The ZEBRA study: Early benefits in quality of life in goserelin-treated vs CMF-treated pre-/perimenopausal patients with node-positive early breast cancerEuropean Journal Of Cancer, 2001
- The emerging role of hormonal ablation as adjuvant therapy in node + and node – pre-/perimenopausal patientsThe Breast, 2001
- Investigation of menstruation recovery after LH-RH agonist therapy for premenopausal patients with breast cancer.Breast Cancer, 2000
- Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized TrialJournal of Clinical Oncology, 2000
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.Journal of Clinical Oncology, 1998
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996
- Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancerJournal of Steroid Biochemistry, 1984